Jude Onyia

CSO Jude Onyia sold 11,000 NBIX shares at $160.25 (scheduled 10b5-1 plan, retains 13,268 options)

Chief Scientific Officer Jude Onyia sold 11,000 shares at $160.25 on 2026-06-01, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares, with a total transaction value of $1,762,710.40. This sale is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, meaning the transaction was scheduled rather than discretionary. The stock's current price of $154.84 sits 4.6% below its 52-week high of $162.39, and the company reports strong fundamentals with net income of $197,900,000.00 on revenue of $814,500,000.00 and annual revenue growth of +21.4%. The insider retains 13,268 non-qualified stock options, maintaining a material position in the company. His prior two sales at NBIX showed mixed outcomes: a -4.2% 30-day return and a -0.9% 30-day return, though 90-day returns were positive at +5.0% and +7.9% respectively.

NBIX Chief Scientific Officer Jude Onyia sells 11,000 shares at $155.53 via pre-arranged 10b5-1 plan; retains 25,846 shares plus 24,268 options.

Jude Onyia, Chief Scientific Officer, executed a scheduled sale of 11,000 shares for $1,710,865.20 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-25, reducing non-derivative holdings by 29.9% from 36,846 to 25,846 shares while retaining 24,268 non-qualified stock options. The sale occurred at $155.53, which is 2.5% below the 52-week high of $162.39, as the stock has risen 20.6% over the past 30 days and 19.7% over 90 days. His prior two sales at NBIX showed mixed outcomes: the 2025-07-09 sale saw 30-day returns of -4.2% but 90-day returns of +5.0%, while the 2025-07-02 sale had 30-day returns of -0.9% and 90-day returns of +7.9%. Because this sale is scheduled rather than discretionary, price timing cannot be inferred as a signal of insider conviction. With NBIX fundamentals showing $814.5M in latest quarterly revenue, $197.9M net income, and 21.4% annual revenue growth, the transaction reflects a routine vest-and-sell within a pre-approved framework.

NBIX Chief Scientific Officer sold 59,819 shares ($7.8M) on 2025-07-09; stock up 7.5% in 30 days, 46.9% in 90 days.

Onyia Jude, Chief Scientific Officer at Neurocrine Biosciences, executed an open-market sale of 59,819 shares at $130.46, reducing his stake by 76.6% from 78,108 to 18,289 shares. The company is trading at 43.19 P/E with strong fundamentals—$572.6M in quarterly revenue, positive net income of $7.9M, and 24.8% annual revenue growth—suggesting no immediate distress signal from the fundamentals. The sale occurred with the stock at a 12.9% discount to its 52-week high of $153.29, and subsequent price action shows the stock advancing 7.5% over the following 30 days and 46.9% over 90 days, indicating the sale was not well-timed relative to near-term momentum. His cross-ticker track record shows only 1 prior sell transaction, limiting pattern evidence at this ticker.

CSO Onyia Jude sold 20,362 shares (52.7% of holdings) at $130.13; stock now $127.88, down 16.6% from 52-week high.

Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences, executed a substantial reduction of his equity stake, selling 20,362 shares for $2.6M and retaining 18,289 shares post-transaction. The sale occurred at $130.13, above the current price of $127.88 but 16.6% below the 52-week high of $153.29. While the company shows solid fundamentals with annual revenue growth of +24.8% and recent quarterly revenue of $572.6M, the executive's decision to divest half his holdings merits attention given his CSO role in a biotech context where senior scientists typically maintain substantial skin-in-the-game. The stock's 90-day gain of +46.1% provides context for the transaction timing relative to recent momentum, though the P/E of 41.39 reflects elevated valuation assumptions typical of growth-stage biotech.